Evidence for cross talk between PPARalpha and p38 MAP kinase.
Roberts
Ruth A
RA
Syngenta CTL, Alderley Park, Macclesfield, SK10 4TJ, United Kingdom. ruth.roberts@aventis.com
D000818:Animals; D002273:Carcinogens / Q000633:toxicity; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic; D022781:Hepatocytes; D007093:Imidazoles / Q000494:pharmacology; D008113:Liver Neoplasms / Q000139:chemically induced / Q000235:genetics; D051379:Mice; D020928:Mitogen-Activated Protein Kinases; D020025:Peroxisome Proliferators; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D020239:Receptor Cross-Talk; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D048051:p38 Mitogen-Activated Protein Kinases
D002273:Carcinogens; D004791:Enzyme Inhibitors; D007093:Imidazoles; D020025:Peroxisome Proliferators; D011725:Pyridines; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; C093642:SB 203580